Your browser is no longer supported. Please, upgrade your browser.
Settings
HGEN [NASD]
Humanigen, Inc.
Index- P/E- EPS (ttm)-3.36 Insider Own28.15% Shs Outstand52.66M Perf Week-1.23%
Market Cap991.54M Forward P/E3.92 EPS next Y4.11 Insider Trans-18.46% Shs Float45.29M Perf Month-7.25%
Income-152.60M PEG- EPS next Q-0.61 Inst Own39.10% Short Float16.55% Perf Quarter-16.30%
Sales0.80M P/S1239.43 EPS this Y-426.20% Inst Trans1.11% Short Ratio5.85 Perf Half Y-10.24%
Book/sh0.32 P/B50.38 EPS next Y30.69% ROA-202.30% Target Price- Perf Year-29.30%
Cash/sh1.51 P/C10.67 EPS next 5Y12.50% ROE-356.10% 52W Range7.50 - 29.20 Perf YTD-7.89%
Dividend- P/FCF- EPS past 5Y43.70% ROI-193.80% 52W High-44.79% Beta-2.34
Dividend %- Quick Ratio1.90 Sales past 5Y- Gross Margin- 52W Low114.93% ATR0.87
Employees10 Current Ratio1.90 Sales Q/Q- Oper. Margin- RSI (14)40.33 Volatility4.56% 5.57%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.91 Prev Close16.58
ShortableYes LT Debt/Eq1.44 Earnings- Payout- Avg Volume1.28M Price16.12
Recom1.80 SMA20-3.54% SMA50-12.27% SMA200-1.22% Volume1,166,036 Change-2.77%
Jun-11-21Initiated Credit Suisse Outperform $28
May-07-21Initiated Oppenheimer Outperform $30
Feb-23-21Initiated JP Morgan Neutral $21
Dec-23-20Initiated National Securities Buy $35
Dec-22-20Initiated Jefferies Buy $27
Oct-21-20Initiated Cantor Fitzgerald Overweight $25
Oct-14-20Initiated H.C. Wainwright Buy $31
Oct-01-20Initiated ROTH Capital Buy $25
Jul-30-21 11:06AM  
Jul-26-21 08:00AM  
Jul-22-21 09:59AM  
Jul-13-21 06:51PM  
Jul-12-21 08:40AM  
Jul-09-21 06:30AM  
Jun-28-21 11:46AM  
Jun-25-21 02:27AM  
Jun-14-21 06:30AM  
Jun-07-21 08:00AM  
Jun-03-21 08:00AM  
May-28-21 09:00AM  
May-26-21 08:30AM  
May-19-21 07:00AM  
May-17-21 08:00AM  
May-13-21 04:01PM  
10:15AM  
May-11-21 04:19AM  
May-05-21 11:53AM  
Apr-21-21 07:00AM  
Apr-19-21 07:00AM  
Apr-09-21 08:19AM  
08:02AM  
Apr-06-21 02:02PM  
Mar-30-21 08:08PM  
Mar-29-21 04:11PM  
07:00AM  
06:00AM  
Mar-19-21 07:00AM  
Mar-12-21 01:30AM  
Mar-10-21 04:01PM  
04:00PM  
Mar-08-21 08:34AM  
Mar-05-21 04:32PM  
Mar-02-21 07:00AM  
Feb-25-21 07:30AM  
Feb-11-21 07:30AM  
Feb-08-21 07:00AM  
Feb-04-21 02:37PM  
Feb-03-21 07:00AM  
Jan-29-21 07:00AM  
Jan-27-21 07:00AM  
07:00AM  
Jan-25-21 01:21PM  
08:30AM  
Jan-22-21 07:00AM  
Jan-10-21 08:00AM  
Jan-05-21 04:30PM  
Dec-28-20 07:00AM  
Dec-20-20 03:40AM  
Dec-17-20 08:00AM  
07:00AM  
Dec-14-20 08:00AM  
Dec-02-20 11:33PM  
Nov-23-20 04:05PM  
Nov-11-20 07:00AM  
Nov-06-20 09:59AM  
08:52AM  
07:00AM  
07:00AM  
Nov-04-20 04:05PM  
Nov-03-20 09:01AM  
07:30AM  
Nov-01-20 05:58AM  
Oct-30-20 02:05PM  
Oct-29-20 07:00AM  
Oct-27-20 04:01PM  
Oct-13-20 12:48PM  
11:00AM  
Oct-05-20 10:20AM  
Oct-02-20 08:00AM  
08:00AM  
07:00AM  
07:00AM  
Sep-23-20 07:30AM  
07:00AM  
Sep-22-20 04:50PM  
04:30PM  
02:25PM  
02:00PM  
Sep-21-20 12:02PM  
Sep-17-20 09:10PM  
08:30PM  
Sep-15-20 07:30AM  
01:00AM  
Sep-14-20 07:00AM  
Sep-04-20 05:00PM  
04:30PM  
Sep-02-20 06:21PM  
08:00AM  
Sep-01-20 06:15PM  
Humanigen, Inc., a clinical stage biopharmaceutical company, develops a portfolio of immuno-oncology and immunology monoclonal antibodies in the United States. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which is in Phase III clinical trial for the treatment of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory B-cell lymphoma, as well as that has completed Phase I clinical trial in patients with chronic myelomonocytic leukemia. It also develops Ifabotuzumab, a humaneered monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005, an anti-EMR1 monoclonal antibody, which is in pre-clinical stage for the treatment of eosinophilic disorders. Humanigen, Inc. has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase Ib/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma; and a cooperative research and development agreement with the Department of Defense to assist in the development of lenzilumab in advance of a potential emergency use authorization for COVID-19. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was incorporated in 2000 and is based in Burlingame, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chappell DaleChief Scientific OfficerJul 29Sale17.0329,394500,703884,029Jul 30 09:01 PM
Chappell DaleChief Scientific OfficerJul 28Sale17.049,692165,162886,233Jul 30 09:01 PM
Chappell DaleChief Scientific OfficerJul 23Sale17.045,58495,155886,960Jul 23 08:32 PM
Chappell DaleChief Scientific OfficerJul 22Sale17.04178,0053,032,796887,379Jul 23 08:32 PM
Chappell DaleChief Scientific OfficerJul 21Sale17.14132,7642,275,124900,729Jul 23 08:32 PM
Chappell DaleChief Scientific OfficerJul 14Sale17.0615,177258,847910,686Jul 16 08:28 PM
Chappell DaleChief Scientific OfficerJul 09Sale17.37296,0365,142,767911,824Jul 09 09:01 PM
Chappell DaleChief Scientific OfficerJul 08Sale17.1748,010824,111934,027Jul 09 09:01 PM
Chappell DaleChief Scientific OfficerJun 25Sale17.801,000,00017,803,500972,361Jun 25 09:01 PM
Chappell DaleChief Scientific OfficerJun 24Sale18.37139,5292,563,8311,047,361Jun 25 09:01 PM
Chappell DaleChief Scientific OfficerJun 23Sale18.28133,1262,434,1821,057,826Jun 25 09:01 PM
Chappell DaleChief Scientific OfficerJun 18Sale18.50402,4807,445,5581,067,811Jun 21 08:57 PM
Chappell DaleChief Scientific OfficerJun 17Sale19.17181,4233,478,4411,097,997Jun 21 08:57 PM
Chappell DaleChief Scientific OfficerJun 16Sale19.41158,4863,076,1871,111,604Jun 21 08:57 PM
Durrant CameronChief Executive OfficerJun 14Sale20.6481,4411,680,93430,000Jun 16 09:40 PM
Jordan Edward P.Chief Commercial OfficerJun 08Option Exercise9.6514,700141,85514,700Jun 09 05:10 PM
Jordan Edward P.Chief Commercial OfficerJun 08Sale20.0814,700295,1760Jun 09 05:10 PM
Chappell DaleChief Scientific OfficerJun 07Sale19.0880,6361,538,7931,124,334Jun 09 04:45 PM
Chappell DaleChief Scientific OfficerJun 04Sale18.46127,0842,346,4151,137,066Jun 04 06:07 PM
Chappell DaleChief Scientific OfficerJun 03Sale18.37191,1543,511,3081,157,132Jun 04 06:07 PM
Chappell DaleChief Scientific OfficerJun 02Sale19.0176,1261,447,2691,187,314Jun 04 06:07 PM
NOMIS BAY LTD.10% OwnerMar 11Sale16.02119,2011,909,6725,380,799Mar 11 08:24 PM
NOMIS BAY LTD.10% OwnerMar 10Sale16.4632,469534,5895,500,000Mar 11 08:24 PM
NOMIS BAY LTD.10% OwnerMar 09Sale17.2483,5681,440,49555,632,469Mar 11 08:24 PM
NOMIS BAY LTD.10% OwnerMar 01Sale18.6514,100262,9515,616,037Mar 01 05:48 PM
NOMIS BAY LTD.10% OwnerFeb 26Sale19.1830,003575,4375,630,137Mar 01 05:48 PM
NOMIS BAY LTD.10% OwnerFeb 25Sale19.172,40246,0455,660,140Mar 01 05:48 PM
NOMIS BAY LTD.10% OwnerFeb 24Sale19.5525,906506,3335,662,542Feb 24 06:27 PM
NOMIS BAY LTD.10% OwnerFeb 22Sale23.2177,3141,794,6905,688,448Feb 24 06:27 PM
NOMIS BAY LTD.10% OwnerFeb 19Sale23.5037,300876,3645,765,762Feb 19 06:02 PM
NOMIS BAY LTD.10% OwnerFeb 18Sale21.7042,408920,0425,803,062Feb 19 06:02 PM
NOMIS BAY LTD.10% OwnerFeb 17Sale19.929,700193,2145,845,470Feb 19 06:02 PM
NOMIS BAY LTD.10% OwnerFeb 13Sale19.6816,423323,2215,855,170Feb 16 06:53 PM
NOMIS BAY LTD.10% OwnerFeb 11Sale21.0155011,5555,871,593Feb 16 06:53 PM
NOMIS BAY LTD.10% OwnerFeb 10Sale21.3910,875232,6055,872,143Feb 10 06:04 PM
NOMIS BAY LTD.10% OwnerFeb 09Sale22.3225,666572,9425,883,018Feb 10 06:04 PM
NOMIS BAY LTD.10% OwnerFeb 08Sale20.7017,732367,0355,908,684Feb 10 06:04 PM
NOMIS BAY LTD.10% OwnerFeb 04Sale21.8847,8621,047,0775,926,416Feb 04 06:28 PM
NOMIS BAY LTD.10% OwnerFeb 03Sale19.2325,000480,8255,974,278Feb 04 06:28 PM
NOMIS BAY LTD.10% OwnerFeb 02Sale20.0372214,4615,999,278Feb 04 06:28 PM
NOMIS BAY LTD.10% OwnerJan 25Sale19.2323,140445,0286,070,000Jan 27 06:04 AM
NOMIS BAY LTD.10% OwnerJan 22Sale20.0871,8921,443,3046,093,140Jan 27 06:04 AM
NOMIS BAY LTD.10% OwnerJan 20Sale18.372,50045,9286,165,032Jan 21 09:00 PM
NOMIS BAY LTD.10% OwnerJan 19Sale21.086,000126,4956,167,532Jan 21 09:00 PM
NOMIS BAY LTD.10% OwnerJan 19Sale19.8150,000990,5006,173,532Jan 19 06:35 PM
NOMIS BAY LTD.10% OwnerJan 15Sale18.2330,000546,8706,223,532Jan 19 06:35 PM
NOMIS BAY LTD.10% OwnerJan 14Sale18.0725,000451,6506,253,532Jan 19 06:35 PM
NOMIS BAY LTD.10% OwnerJan 12Sale18.4314,577268,6136,278,532Jan 13 05:22 PM
NOMIS BAY LTD.10% OwnerJan 11Sale19.0010,423198,0376,293,109Jan 13 05:22 PM
NOMIS BAY LTD.10% OwnerDec 28Sale22.2050011,1016,303,532Dec 31 04:30 PM
NOMIS BAY LTD.10% OwnerDec 24Sale22.058,401185,2346,304,032Dec 28 05:17 PM
NOMIS BAY LTD.10% OwnerDec 23Sale21.0945,000948,8706,312,433Dec 28 05:17 PM
NOMIS BAY LTD.10% OwnerDec 22Sale20.0050,0001,000,0006,357,433Dec 23 04:06 PM
NOMIS BAY LTD.10% OwnerDec 21Sale19.4625,000486,4456,407,433Dec 23 09:17 AM
NOMIS BAY LTD.10% OwnerDec 18Sale15.7662,700988,3216,469,733Dec 23 09:17 AM